glp 1 for overweight not obese GLP-1 Agonists In Obesity Ten Top Tips for the

Kicking off the forum, Kat Cole spoke on a panel exploring the intersection of metabolic hormones, patient experience, and market innovation

The primary drivers

Healthier insulin response

Here, emulating a clinical trial, the authors show that GLP1-RA use in patients with CKD is associated with lower rate of acute healthcare utilization, all-cause death and kidney events compared to DPP4i.

Fitness club Equinox is partnering with Function Health, a longevity health-tech startup founded by Dr

NRD per 1000 people 5.57 (6.61 to 4.53)), cannabis use (0.86 (0.81 to 0.90), NRD 2.25 (3.00 to 1.50)), cocaine use (0.80 (0.72 to 0.88), NRD 0.97 (1.37 to 0.57)), nicotine use (0.80 (0.74 to 0.87), NRD 1.64 (2.19 to 1.09)), and opioid use (0.75 (0.67 to 0.85), NRD 0.86 (1.19 to 0.52)), and other SUDs (0.87 (0.81 to 0.94), NRD 1.12 (1.68 to 0.55)) and composite outcome of all incident SUDs (0.86 (0.83 to 0.88), NRD 6.61 (7.95 to 5.26))